- Home
- GCMG vs MNPR Comparison
GCMG vs MNPR Comparison
Compare GCMG & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMG
- MNPR
- Stock Information
- Founded
- GCMG 1971
- MNPR 2014
- Country
- GCMG United States
- MNPR United States
- Employees
- GCMG N/A
- MNPR N/A
- Industry
- GCMG Finance/Investors Services
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- GCMG Finance
- MNPR Health Care
- Exchange
- GCMG Nasdaq
- MNPR Nasdaq
- Market Cap
- GCMG 611.5M
- MNPR 531.6M
- IPO Year
- GCMG N/A
- MNPR 2019
- Fundamental
- Price
- GCMG $11.26
- MNPR $76.17
- Analyst Decision
- GCMG Buy
- MNPR Strong Buy
- Analyst Count
- GCMG 4
- MNPR 13
- Target Price
- GCMG $14.88
- MNPR $97.83
- AVG Volume (30 Days)
- GCMG 837.5K
- MNPR 146.8K
- Earning Date
- GCMG 11-05-2025
- MNPR 11-13-2025
- Dividend Yield
- GCMG 4.29%
- MNPR N/A
- EPS Growth
- GCMG N/A
- MNPR N/A
- EPS
- GCMG 0.32
- MNPR N/A
- Revenue
- GCMG $543,085,000.00
- MNPR N/A
- Revenue This Year
- GCMG $4.88
- MNPR N/A
- Revenue Next Year
- GCMG $11.59
- MNPR N/A
- P/E Ratio
- GCMG $34.93
- MNPR N/A
- Revenue Growth
- GCMG 17.40
- MNPR N/A
- 52 Week Low
- GCMG $11.19
- MNPR $16.26
- 52 Week High
- GCMG $14.48
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- GCMG 28.78
- MNPR 42.92
- Support Level
- GCMG $11.55
- MNPR $75.00
- Resistance Level
- GCMG $11.73
- MNPR $89.03
- Average True Range (ATR)
- GCMG 0.11
- MNPR 6.63
- MACD
- GCMG 0.00
- MNPR -1.13
- Stochastic Oscillator
- GCMG 11.11
- MNPR 8.64
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.